The Food and Drug Administration (FDA) recently announced plans to integrate artificial intelligence (AI) tools into its review processes for drugs and medical devices. This initiative aims to expedite approval timelines by assisting scientific reviewers in processing data more efficiently. However, the role of AI in determining the safety and effectiveness of drugs has sparked debate among industry observers. While the potential for quicker approvals is welcomed, there are concerns about the extent to which AI might take over critical decision-making processes, traditionally managed by human experts.
Jason Conaty, counsel at Hogan Lovells, emphasized the importance of implementing “guardrails” and ensuring “human oversight” to address challenges associated with generative AI. The balance between leveraging AI for administrative tasks and preserving the integrity of scientific conclusions remains a key point of contention.
For more detailed insights into the FDA’s strategy and the reactions from industry stakeholders, refer to the original article on Law.com.